Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2009 1
2010 3
2011 1
2012 2
2014 3
2015 2
2016 6
2017 7
2018 9
2019 6
2020 7
2021 5
2022 3
2023 5
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Results by year

Filters applied: . Clear all
Page 1
Tumour-agnostic therapies.
Looney AM, Nawaz K, Webster RM. Looney AM, et al. Among authors: webster rm. Nat Rev Drug Discov. 2020 Jun;19(6):383-384. doi: 10.1038/d41573-020-00015-1. Nat Rev Drug Discov. 2020. PMID: 32494047 No abstract available.
The malignant melanoma market.
Parra LM, Webster RM. Parra LM, et al. Among authors: webster rm. Nat Rev Drug Discov. 2022 Jul;21(7):489-490. doi: 10.1038/d41573-022-00075-5. Nat Rev Drug Discov. 2022. PMID: 35477778 No abstract available.
The endometrial carcinoma market.
Vinuesa L, Webster RM. Vinuesa L, et al. Among authors: webster rm. Nat Rev Drug Discov. 2022 Apr;21(4):255-256. doi: 10.1038/d41573-022-00016-2. Nat Rev Drug Discov. 2022. PMID: 35064241 No abstract available.
Bispecific antibodies in oncology.
Esfandiari A, Cassidy S, Webster RM. Esfandiari A, et al. Among authors: webster rm. Nat Rev Drug Discov. 2022 Jun;21(6):411-412. doi: 10.1038/d41573-022-00040-2. Nat Rev Drug Discov. 2022. PMID: 35246638 No abstract available.
The hepatocellular carcinoma market.
Dawkins J, Webster RM. Dawkins J, et al. Among authors: webster rm. Nat Rev Drug Discov. 2019 Jan;18(1):13-14. doi: 10.1038/nrd.2018.146. Epub 2018 Aug 31. Nat Rev Drug Discov. 2019. PMID: 30168534 No abstract available.
The prostate cancer drug market.
do Pazo C, Webster RM. do Pazo C, et al. Among authors: webster rm. Nat Rev Drug Discov. 2021 Sep;20(9):663-664. doi: 10.1038/d41573-021-00111-w. Nat Rev Drug Discov. 2021. PMID: 34145436 No abstract available.
The breast cancer drug market.
Wilcock P, Webster RM. Wilcock P, et al. Among authors: webster rm. Nat Rev Drug Discov. 2021 May;20(5):339-340. doi: 10.1038/d41573-021-00018-6. Nat Rev Drug Discov. 2021. PMID: 33483705 No abstract available.
The oncology market for antibody-drug conjugates.
do Pazo C, Nawaz K, Webster RM. do Pazo C, et al. Among authors: webster rm. Nat Rev Drug Discov. 2021 Aug;20(8):583-584. doi: 10.1038/d41573-021-00054-2. Nat Rev Drug Discov. 2021. PMID: 33762691 No abstract available.
The non-small-cell lung cancer drug market.
Nawaz K, Webster RM. Nawaz K, et al. Among authors: webster rm. Nat Rev Drug Discov. 2023 Apr;22(4):264-265. doi: 10.1038/d41573-023-00017-9. Nat Rev Drug Discov. 2023. PMID: 36690751 No abstract available.
A joint international consensus statement for measuring quality of survival for patients with childhood cancer.
van Kalsbeek RJ, Hudson MM, Mulder RL, Ehrhardt M, Green DM, Mulrooney DA, Hakkert J, den Hartogh J, Nijenhuis A, van Santen HM, Schouten-van Meeteren AYN, van Tinteren H, Verbruggen LC, Conklin HM, Jacola LM, Webster RT, Partanen M, Kollen WJW, Grootenhuis MA, Pieters R, Kremer LCM; International Childhood Cancer Outcome Project participants. van Kalsbeek RJ, et al. Among authors: webster rt. Nat Med. 2023 Jun;29(6):1340-1348. doi: 10.1038/s41591-023-02339-y. Epub 2023 Jun 15. Nat Med. 2023. PMID: 37322119 Review.
63 results